1-(1 H-1, 2, 4-三唑-1-基)-2-(2, 4-二氟苯基)-3-[N-异丙基-N-(4-取代苄基)]-2-丙醇的合成及抗真菌活性

闫永正; 柴晓云; 邹燕; 俞世冲; 吴秋业; 闫永正; 柴晓云; 邹燕; 俞世冲; 吴秋业

[1]

Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis[J]. Clin Infect Dis, 1999, 29 (2): 234.

[2]

Nuccil M, Marr KA. Emerging fungal diseases[J]. Clin Infect Dis, 2005, 41: 521.

[3]

Zhao QJ, Song Y, Hu HG, et al. Design, synthesis and antifungal activity of novel triazole derivatives[J]. Chin Chem Lett, 2007, 18: 670.

[4]

Zhao QJ, Hu HG, Li YW, et al. Design, Synthesis, and antifungal activities of novel 1H-triazole derivatives based on the structure of the active site of fungal lanosterol 14a-demethylase (CYP51)[J]. Chem Biol, 2007, 4: 1472.

[5]

吴秋业,杨济秋. 4-{[2-(1H-咪唑基)-1-(4-取代苯基)乙氧基]甲基}苯甲酸类化合物的合成及其抑制血小板聚集的作用[J]. 药学学报,1991, 26(10): 741.

[6]

孙青龑, 刘超美, 赵红兵, 等. 1-(1H-1, 2, 4-三唑-1-基)-2-(2, 4-二氟苯基)-3-含硫侧链-2-丙醇类化合物的合成及抗真菌活性[J]. 第二军医大学学报, 2001, 22(9): 871.

[7]

National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard.Document M27-A2[S].PA:Wayne: 2002.